An AI Digital Cell Clone™ Factory

ThinkingNode Life Science (TLS) is the first AI techbio company to develop Large Reasoning Models™ (LRM) to generate the most advanced Human Cell Reasoning Foundation Model.

Applied to drug R&D, TLS's Digital Cell Clone™ platform can produce the most advanced human digital cell simulations in less than an hour, which can be used to predict and understand cellular behavior and response to drugs for safety, efficacy, and specificity.

As the cell is the fundamental unit of biology, TLS can create value at multiple points throughout the entire drug R&D process. Unlike most AI drug R&D companies that focus on drug design, TLS simulates cellular responses to drugs before and after each stage of pharmaceutical R&D to de-risk by providing critical insights for decision-making. TLS's Digital Cell Clones have been used for novel target discovery, target validation, biomarker discovery, indication expansion, drug combination, drug comparison, drug response prediction, mechanism of action validation, and patient stratification.

TNL’s Large Reasoning Models™ (LRM) have been created based on the second generation of MARS (Macro-connectionist Reasoning Reasoning System). The first generation of MARS was successfully used in Dr. Pham first AI company (acquired by Nasdaq: EPNY for $637M). The LRMs are built on extensive knowledge bases characterizing cellular structure and function, and then further refined with gene expression data through a proprietary process, called Digital Cell Differentiation™, to produce specific Digital Cell Clones of interest. The result is highly unique, powerful cell simulations which are capable of predicting dynamic cellular responses in an unprecedented, scalable digital platform.

The Whole-Cell-Centric Approach For
Drug R&D

Most biotech pharma activities focus on drug discovery & development using known published targets because the identification of novel targets is complex and requires extensive fundamental research and knowledge. It is why it is usually done by academic institutions. Scientists must identify the biochemical pathway that is involved in the disease. This pathway-centric approach has yielded excellent results for many health conditions.

However, most diseases are the result of the whole-cell behavior and not just of a few biochemical pathways. Unfortunately, no humans can handle the dynamic complexity level of the whole-cell network. This explains why, despite great results, the limited pathway-centric approach failed so many times and can produce drugs with harmful side effects.

TLS’s Human Digital Cell Clones allow a more extensive, faster, and cheaper way to provide novel unpublished targets/biomarkers identification, drug repurposing, drug combination, and clinical trials optimization.

In addition, these Human Digital Cell Clones allow the introduction of a new major phase for drug R&D: Human Cell Safety/Efficacy/Specificity Simulations before any lengthy and costly drug development or in vivo testing.

TLS whole-cell-centric approach brings a transformative shift for drug R&D.